上海莱士(002252.SZ)：人纤维蛋白原获得《药品注册证书》

Core Viewpoint - Shanghai Raas (002252.SZ) announced that its wholly-owned subsidiary, Tonglu Biopharmaceutical Co., Ltd., has recently received a Drug Registration Certificate from the National Medical Products Administration for its product, Human Fibrinogen [1] Group 1 - The product, Human Fibrinogen, is derived from healthy human plasma, which is separated, purified, and treated for virus removal and inactivation before being freeze-dried [1] - The indication for Tonglu Biopharmaceutical's product is congenital fibrinogen deficiency or reduction [1]